La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Atara Biotherapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Atara Biotherapeutics..

Atara Biotherapeutics (NASDAQ:ATRA) Azioni, Catena delle Opzioni

Atara Biotherapeutics

Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).

Atara Biotherapeutics, Inc. - Common Stock

Atara Biotherapeutics Inc

WIIM

ATRA

Atara Biotherapeutics shares are trading higher after the company reported better-than-expected Q3 sales results. Also, Canaccord Genuity maintained a Buy rating on the stock and raised its price target from $13 to $21.

Canaccord Genuity analyst John Newman maintains Atara Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) with a Buy and raises the price target from $13 to $21.

News

Price Target

Analyst Ratings

Canaccord Genuity Maintains Buy on Atara Biotherapeutics, Raises Price Target to $21

Atara Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) reported quarterly losses of $(2.93) per share which missed the analyst consensus estimate of $(2.50) by 17.2 percent. The company reported quarterly sales of $40.190 million which beat the analyst consensus estimate of $35.168 million by 14.28 percent. This is a 1.78K percent increase over sales of $2.138 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Atara Biotherapeutics Q3 2024 GAAP EPS $(2.93) Misses $(2.50) Estimate, Sales $40.190M Beat $35.168M Estimate

ABOS

ABSI

ACNT

ACTG

AENT

AGEN

AIOT

AIRG

ALIT

ALTG

AMBC

AMPS

AMTX

APEI

AREB

ARIS

ARMN

AUTL

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AXSM

AZTA

BHIL

BLDE

BLFS

BLTE

The Beachbody Company, Inc. Class A Common Stock

BODI

BRTX

BTMD

BTTR

BWAY

BXSL

BZFD

CAMT

CART

CATX

CAVA

CBAT

CBLL

CCLD

CGEN

CHGG

CHMI

CLSD

CNNE

CRNX

CRON

CRVS

CRWS

CVAC

CXAI

DAVA

DAVE

DRCT

DYAI

EARN

EGAN

ELMD

ETON

EVCM

EVGO

EYEN

FENG

FGEN

FIHL

FLNG

FOUR

FTCI

GENI

GENK

GMGI

GOVX

GRAL

GRDN

GROV

GRPN

GRVY

Earnings Scheduled For November 12, 2024

Atara Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) is gearing up to announce its quarterly earnings on Tuesday, 2024-11-12. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Atara Biotherapeutics will report an earnings per share (EPS) of $-1.93.
Atara Biotherapeutics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Performance in Previous Earnings</h3>
The company's EPS missed by $1.54 in the last quarter, leading to a 3.22% increase in the share price on the following day.
Here's a look at Atara Biotherapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.56</td>
<td>-6.50</td>
<td>-12</td>
<td>-16.5</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-3.10</td>
<td>-5.75</td>
<td>-14</td>
<td>-16.5</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.0%</td>
<td>-3.0%</td>
<td>-1.0%</td>
<td>-6.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731348105_0.png" alt="eps graph" />
<h3>Tracking Atara Biotherapeutics's Stock Performance</h3>
Shares of Atara Biotherapeutics were trading at $11.31 as of November 08. Over the last 52-week period, shares are up 41.23%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/ATRA/earnings">To track all earnings releases for Atara Biotherapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights into Atara Biotherapeutics's Upcoming Earnings

Hyllengren's Base Salary Increased To $520,000 Annually; No Related Person Transactions Or Arrangements Involved In Promotion

Management

Atara Biotherapeutics Appoints Eric Hyllengren As Chief Operating Officer In Addition To His Role As Chief Financial Officer

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining around 0.2% on Wednesday.
The Dow traded down 0.08% to 40,906.17 while the NASDAQ rose 0.21% to 17,172.66. The S&amp;P 500 also fell, dropping, 0.03% to 5,527.51.
Check This Out:<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/40706790/top-3-consumer-stocks-that-could-blast-off-this-quarter"> Top 3 Consumer Stocks That Could Blast Off This Quarter</a>
Leading and Lagging Sectors Utilities shares climbed by 0.6% on Wednesday.
In trading on Wednesday, energy shares fell by 0.9%.
Top Headline
Shares of Dollar Tree, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) dipped over 21% on Wednesday after the company reported worse-than-expected second-quarter 2024 earnings.
The discount variety stores chain reported an adjusted EPS of 67 cents, missing the consensus of $1.04, and down 26.4% year over year. The company reported sales of $7.38 billion, up marginally by 0.07%, missing the consensus of $7.5 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Faraday Future Intelligent Electric Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIE#NASDAQ">FFIE</a>) shares shot up 43% to $4.8986.</li>
<li>Shares of Atara Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) got a boost, surging 32% to $9.00. The company announced a $36 million registered direct offering of 758,900 shares at $8.25 per share.</li>
<li>WiSA Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WISA#NASDAQ">WISA</a>) shares were also up, gaining 69% to $2.30 after the company announced that it executed a definitive asset purchase agreement to purchase the Datavault intellectual property and information technology assets of privately held Data Vault Holdings for $210 million.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Athira Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHA#NASDAQ">ATHA</a>) shares dropped 78% to $0.6361 after the company released topline results from its Phase 2/3 LIFT-AD clinical trial of fosgonimeton for mild-to-moderate Alzheimer's disease (AD).</li>
<li>Shares of Oragenics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGEN#NYSE">OGEN</a>) were down 45% to $0.59. Oragenics priced its $4.45 million public offering of 8,106,584 shares at $0.55 per share.</li>
<li>Psyence Biomedical Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) was down, falling 33% to $0.2482. The company announced it entered into a worldwide, exclusive royalty-bearing IP licensing agreement with PsyLabs.</li>
</ul>
Commodities In commodity news, oil traded down 1% to $69.68 while gold traded up 0.2% at $2,527.20.
Silver traded up 0.9% to $28.595 on Wednesday, while copper fell 0.3% to $4.0805.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 0.97%, Germany's DAX fell 0.83% and France's CAC 40 fell 0.98%. Spain's IBEX 35 Index fell 0.58%, while London's FTSE 100 fell 0.35%.
The S&amp;P Global UK services PMI climbed to 53.7 in August from 52.5 in the prior month. Producer prices in the Eurozone rose 0.8% month-over-month in July versus a revised 0.6% increase in June. The HCOB Eurozone composite PMI was revised lower to 51 in August versus a flash reading of 51.2.
Asia Pacific Markets
Asian markets closed lower on Wednesday, with Japan's Nikkei 225 falling 4.24%, Hong Kong's Hang Seng Index falling 1.10%, China's Shanghai Composite Index declining 0.67% and India's BSE Sensex falling 0.25%.
The HSBC India Composite PMI rose to 60.7 in August versus a flash reading of 60.5. Caixin China General Composite PMI came in unchanged at 51.2 in August.
Economics
The trade deficit in the U.S. increased to $78.8 billion in July, recording the biggest gap since June 2022, versus a gap of $73 billion in June.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40708182/wall-streets-most-accurate-analysts-weigh-in-on-3-energy-stocks-with-over-7-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Energy Stocks With Over 7% Dividend Yields</a></li>
</ul>

Equities

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

ATHA

DLTR

FFIE

OGEN

WISA

Crude Oil Down 1%; Dollar Tree Shares Tumble After Downbeat Earnings

Atara Biotherapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) shares are trading higher by 30.7% to $8.87 Wednesday morning. The company announced a $36 million registered direct offering of 758,900 shares at <a href="https://www.benzinga.com/pressreleases/24/09/b40695909/atara-biotherapeutics-announces-36-million-registered-direct-offering">$8.25 per share.</a>
The offering, priced at a 15% premium to the company&#8217;s recent average stock price, involves the sale of 758,900 shares at $8.25 per share and 3,604,780 pre-funded warrants at $8.2499 per share. The pre-funded warrants are almost immediately exercisable.&nbsp;
The investors include Redmile Group, EcoR1 Capital, Adiumentum Capital Management and a large public biotech company. The offering is expected to close around September 5.
Additionally, Greg Ciongoli, founder of Adiumentum Capital, will join Atara&#8217;s Board of Directors. The funds will be used for working capital and general corporate purposes.
Read Also: <a href="https://www.benzinga.com/markets/equities/24/09/40696921/traders-bet-aggressively-on-rate-cuts-ahead-of-jobs-data-5-etfs-to-watch-this-week">Traders Bet Aggressively On Rate Cuts Ahead Of Jobs Data: 5 ETFs To Watch This Week</a>
<h2 class="wp-block-heading">How To Buy ATRA Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Atara Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>)'s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, ATRA has a 52-week high of $49.00 and a 52-week low of $4.96.

Atara Biotherapeutics (ATRA) Stock Is Up 20%: What's Going On?

Shares of GitLab Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLB#NASDAQ">GTLB</a>) rose sharply in today's pre-market trading after the company reported better-than-expected second-quarter financial results and issued <a href="https://www.benzinga.com/news/earnings/24/09/40696793/gitlab-stock-climbs-on-q2-results-strong-fy-25-guidance">FY25 guidance above estimates.</a>
GitLab reported quarterly earnings of 15 cents per share, which beat the analyst consensus estimate by 50%. Quarterly revenue came in at $182.6 million, which beat the analyst consensus estimate of $176.889 million by 3.23%.
GitLab shares jumped 16.8% to $52.21 in the pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>WiSA Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WISA#NASDAQ">WISA</a>) gained 63.2% to $2.22 in pre-market trading as the company said it has executed a definitive asset purchase agreement to purchase the Datavault&#xAE; intellectual property and information technology assets of privately held Data Vault Holdings Inc.</li>
<li>Conifer Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNFR#NASDAQ">CNFR</a>) rose 39.1% to $1.60 in today's pre-market trading. Conifer Holdings shares jumped 74% on Tuesday after the company announced that it completed the sale of its insurance agency operations for a $45 million consideration. The company appointed Brian Roney As CEO.</li>
<li>LogicMark, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) gained 29.4% to $0.2618 in pre-market trading after gaining over 12% on Monday.</li>
<li>Atara Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) gained 17.2% to $7.99 in pre-market trading. The company announced a $36 million registered direct offering of 758900 shares at $8.25 per share.</li>
<li>Tantech Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TANH#NASDAQ">TANH</a>) gained 16% to $0.1613 in the pre-market trading session.</li>
<li>BTCS Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTCS#NASDAQ">BTCS</a>) gained 10% to $1.10 in pre-market trading after dipping around 15% on Tuesday.</li>
<li>Genelux Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLX#NASDAQ">GNLX</a>) rose 9.1% to $2.27 in pre-market trading after declining around 4% on Tuesday.</li>
<li>Clover Health Investments, Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>) gained 8.4% to $2.71 in pre-market trading after subsidiary Iowa Clinic signed a multi-year agreement with Counterpart Health to deploy AI technology across hundreds of Midwest providers.</li>
<li>Astera Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) gained 4% to $40.66 in pre-market trading after dipping 9% on Tuesday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Athira Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHA#NASDAQ">ATHA</a>) fell 72.7% to $0.7739 in pre-market trading after the company announced its Phase 2/3 LIFT-AD clinical trial for Fosgonimeton in mild-to-moderate Alzheimer&#8217;s disease did not meet its primary or key secondary endpoints.</li>
<li>Oragenics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGEN#NYSE">OGEN</a>) shares fell 32.2% to $0.7254 in pre-market trading after dipping more than 15% on Tuesday. Oragenics, last month, announced the filing completion for its ONP-002 drug in anticipation of its Phase IIa clinical trail in concussed patients.</li>
<li>Focus Universal Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCUV#NASDAQ">FCUV</a>) shares fell 16.4% to $0.2530 in pre-market trading after gaining more than 12% on Tuesday.</li>
<li>Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) shares declined 16.2% to $1.76 in pre-market trading. The company was granted #12077515 for selective histone deacetylase inhibitors.</li>
<li>Zscaler, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) fell 15.2% to $163.70 in pre-market trading following fourth-quarter earnings.</li>
<li>Asana, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASAN#NYSE">ASAN</a>) shares declined 14.6% to $11.35 in pre-market trading. Asana reported upbeat results for its second quarter but issued weak guidance for the third quarter.</li>
<li>PagerDuty, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PD#NYSE">PD</a>) fell 14.4% to $15.66 in today's pre-market trading. PagerDuty reported better-than-expected earnings for its second quarter, while sales missed estimates.</li>
<li>Elevai Labs Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELAB#NASDAQ">ELAB</a>) shares fell 11.3% to $0.2839 in pre-market trading. Elevai Labs shares gained around 20% on Tuesday after its subsidiary, Elevai Skincare, announced data results that demonstrated the potential of its proprietary Elevai Exosomes in hair restoration.</li>
<li>Motorsport Games Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSGM#NASDAQ">MSGM</a>) shares dipped 11.3% to $1.16 in pre-market trading after gaining 10% on Tuesday.</li>
<li>Sify Technologies Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIFY#NASDAQ">SIFY</a>) declined 9.6% to $0.5971 in pre-market trading after jumping around 100% on Tuesday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/09/40700996/dow-tumbles-over-600-points-nasdaq-dips-3-amid-plunge-in-nvidia-fear-index-remains-in-greed-zone">Dow Tumbles Over 600 Points, Nasdaq Dips 3% Amid Plunge In Nvidia: Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>

Pre-Market Outlook

Movers

ALAB

ASAN

BTCS

CLOV

CNFR

ELAB

FCUV

GNLX

GTLB

LGMK

MSGM

SHPH

SIFY

TANH

Why GitLab Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket

Atara Biotherapeutics shares are trading higher. The company announced a $36 million registered direct offering of 758900 shares at $8.25 per share.

Offerings

Atara Biotherapeutics Announces $36M Registered Direct Offering Of 758,900 Shares At $8.25/Share

HC Wainwright &amp; Co. analyst Robert Burns reiterates Atara Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) with a Neutral.

Reiteration

HC Wainwright & Co. Reiterates Neutral on Atara Biotherapeutics

Mizuho analyst Salim Syed upgrades Atara Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) from Neutral to Outperform and lowers the price target from $25 to $18.

Upgrades

Mizuho Upgrades Atara Biotherapeutics to Outperform, Lowers Price Target to $18

Canaccord Genuity analyst John Newman maintains Atara Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) with a Buy and maintains $13 price target.

Canaccord Genuity Maintains Buy on Atara Biotherapeutics, Maintains $13 Price Target

It plans to initiate ATA3219 Systemic Lupus Erythematosus trial in the&nbsp;fourth quarter, including the cohort without lymphodepletion, with initial data expected in mid-2025.

Guidance

Atara Biotherapeutics Expects Cash Runway Into 2027, Enabling Key Pipeline Readouts

Atara Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) reported quarterly losses of $(3.10) per share which missed the analyst consensus estimate of $(1.56) by 98.72 percent. The company reported quarterly sales of $28.64 million which missed the analyst consensus estimate of $39.99 million by 28.38 percent. This is a 2.89K percent increase over sales of $957.00 thousand the same period last year.

Atara Biotherapeutics Q2 2024 GAAP EPS $(3.10) Misses $(1.56) Estimate, Sales $28.64M Miss $39.99M Estimate

Goldman Sachs analyst Tommie Reerink maintains Atara Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) with a Sell and lowers the price target from $12.5 to $11.

Goldman Sachs Maintains Sell on Atara Biotherapeutics, Lowers Price Target to $11

Prescription Drug User Fee Act (PDUFA) Target Action Date of January 15, 2025
If Approved, Tab-cel Would Be First Approved Therapy in U.S. for EBV+ PTLD
BLA Acceptance Triggers $20 Million Milestone Payment from Pierre Fabre Laboratories, with Additional $60 Million Milestone if Approved by FDA

Biotech

General

Atara Biotherapeutics Receives FDA Acceptance And Priority Review Of Biologics License Application For Tabelecleucel For Treatment Of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

Shares of Ovid Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OVID#NASDAQ">OVID</a>) dipped 65.7% to $1.1285 after Takeda&#8217;s Skyline study in Dravet syndrome missed its primary endpoint.
Takeda Pharmaceutical Co Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAK#NYSE">TAK</a>) announced topline data from its SKYLINE and SKYWAY Phase 3 studies of Soticlestat (TAK-935) for the treatment of Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS).
AMMO shares dipped 19.1% to $2.0306 on Friday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Interactive Strength Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRNR#NASDAQ">TRNR</a>) shares climbed 148% to $7.07 after dipping 19% on Friday.</li>
<li>Mustang Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIO#NASDAQ">MBIO</a>) shares jumped 145% to $0.32 after the company announced safety and efficacy data from the complete Waldenstrom Macroglobulinemia cohort of its Phase 1/2 clinical trial of MB-106, showing an overall response rate of 90% with one patient remaining in complete remission at 31 months.</li>
<li>Allego N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLG#NASDAQ">ALLG</a>) gained 126.4% to $1.6750 after the company and its majority shareholder, Meridiam, announced a transaction framework agreement under which Meridiam will launch a tender offer for all issued and outstanding Allego shares not owned by Meridiam, with the option to tender shares for $1.70 per share in cash.</li>
<li>Scinai Immunotherapeutics Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNI#NASDAQ">SCNI</a>) shares gained 92.6% to $6.74 after surging 24% on Friday. Scinai Immunotherapeutics, last week, received a non-binding Letter of Intent from the European Investment Bank for converting loan into equity.</li>
<li>TRxADE HEALTH, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDS#NASDAQ">MEDS</a>) rose 47% to $9.50.</li>
<li>The Aaron&#8217;s Company, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAN#NYSE">AAN</a>) gained 32.2% to $9.97 after the company announced that it entered into a definitive agreement to be acquired by IQVentures Holdings.</li>
<li>AgriFORCE Growing Systems Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGRI#NASDAQ">AGRI</a>) jumped 27% to $0.1044 after the company announced a $1 million share repurchase program.</li>
<li>Xponential Fitness, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPOF#NYSE">XPOF</a>) surged 21.3% to $13.68. Xponential Fitness announced the appointment of Mark King as Chief Executive Officer.</li>
<li>Silynxcom Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYNX#NASDAQ">SYNX</a>) gained 21.8% to $3.14.</li>
<li>Venus Concept Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) gained 13.6% to $1.0650 after the company announced that it has entered a new strategic resurfacing and skin tightening device supply arrangement with Skin Laundry Holdings.</li>
<li>Envirotech Vehicles, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVTV#NASDAQ">EVTV</a>) rose 12.8% to $1.4899.</li>
<li>CNS Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) gained 12.8% to $3.1459. CNS Pharmaceuticals recently announced pricing of registered direct offering and concurrent private placement.</li>
<li>ENDRA Life Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) gained 11.8% to $0.1159 after a 13G filing showed a 9.99% passive stake from S.H.N. Financial Investments Ltd.</li>
<li>Lexicon Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) climbed 10.5% to $2.0099. HC Wainwright &amp; Co. analyst Joseph Pantginis initiated coverage on Lexicon Pharmaceuticals with a Buy rating and announced a price target of $10.</li>
<li>XTL Biopharmaceuticals Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTLB#NASDAQ">XTLB</a>) shares climbed 10.5% to $2.31 after falling around 5% on Friday. XTL recently entered into definitive agreement to acquire The Social Proxy.</li>
<li>Mirum Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRM#NASDAQ">MIRM</a>) gained 10.2% to $28.58. Mirum&#8217;s Volixibat achieved interim analyses in VANTAGE PBC and VISTAS PSC studies.</li>
<li>Ouster, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OUST#NYSE">OUST</a>) shares rose 8.5% to $11.21. Ouster Director Virginia Boulet bought a total of 10,000 shares at an average price of $10.30.</li>
<li>Primo Water Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRMW#NASDAQ">PRMW</a>) gained 7.8% to $24.08 after the company and BlueTriton agreed to merge.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Aerovate Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVTE#NASDAQ">AVTE</a>) shares dipped 90.8% to $2.26 after the company reported 24-week topline results from phase 2b portion of IMPAHCT evaluating AV-101 for pulmonary arterial hypertension.</li>
<li>Kaival Brands Innovations Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KAVL#NASDAQ">KAVL</a>) shares dipped 33% to $3.9950. Kaival Brands Innovations Group shares jumped 338% on Friday after the company announced a $5 million offering of 3,012,048 units at $1.66 per unit.</li>
<li>Bluejay Diagnostics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) fell 29.4% to $0.36 in pre-market trading after jumping 12% on Friday.</li>
<li>Workhorse Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKHS#NASDAQ">WKHS</a>) declined 26% to $2.22. Workhorse announced a 1-for-20 reverse stock split of its common stock last week after shareholders approved the move at the company's annual meeting of stockholders in May.</li>
<li>AMC Networks Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMCX#NASDAQ">AMCX</a>) fell 25.7% to $11.67 after the company announced a private offering of $125 million of convertible senior notes.</li>
<li>iPower Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IPW#NYSE">IPW</a>) shares fell 24.4% to $2.49 after the company announced a $5 million registered direct offering.</li>
<li>Scorpius Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCPX#NASDAQ">SCPX</a>) fell 21.3% to $0.0763 after the company received NYSE American notice of delisting and reported plans to appeal.</li>
<li>Atara Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) declined 20.8% to $0.4044. Atara Biotherapeutics announced a 1-for-25 reverse stock split.</li>
<li>22nd Century Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) dipped 20.7% to $0.6405.</li>
<li>SELLAS Life Sciences Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLS#NASDAQ">SLS</a>) fell 20.6% to $1.19. SELLAS Life Sciences announced review of ongoing Phase 3 REGAL clinical trial of Galinpepimut-S in acute myeloid leukemia by IDMC.</li>
<li>Virgin Galactic Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPCE#NYSE">SPCE</a>) dipped 19.6% to $11.00.</li>
<li>Feutune Light Acquisition Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLFV#NASDAQ">FLFV</a>) shares fell 18.5% to $7.99.</li>
<li>MYT Netherlands Parent B.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYTE#NASDAQ">MYTE</a>) declined 13.1% to $4.31.</li>
<li>Biomea Fusion, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>) fell 12.8% to $4.9190.</li>
<li>BIMI Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIMI#NASDAQ">BIMI</a>) shares fell 12.6% to $1.92 after gaining 23% on Friday.</li>
<li>Cemtrex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CETX#NASDAQ">CETX</a>) fell 12.2% to $0.2451.</li>
<li>La Rosa Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRHC#NASDAQ">LRHC</a>) shares declined 11.1% to $1.04. La Rosa Holdings shares jumped around 76% on Friday after the company filed a request for the withdrawal of its registration statement on a Form S-1.</li>
<li>Evotec SE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NYSE">EVO</a>) shares declined 10.5% to $4.07.</li>
<li>ZKH Group Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZKH#NYSE">ZKH</a>) fell 10.2% to $3.5850. ZKH Group recently announced a $50 million share repurchase program.</li>
<li>Bitdeer Technologies Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTDR#NASDAQ">BTDR</a>) declined 9% to $9.05.</li>
<li>FuelCell Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCEL#NASDAQ">FCEL</a>) fell 6.8% to $0.7636.</li>
<li>Louisiana-Pacific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPX#NYSE">LPX</a>) declined 6.3% to $86.25 after Goldman Sachs downgraded the stock from Neutral to Sell and lowered its price target from $89 to $81.</li>
<li>Coeur Mining, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CDE#NYSE">CDE</a>) fell 5.3% to $5.44.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/24/06/39357134/wall-streets-most-accurate-analysts-spotlight-on-3-materials-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Materials Stocks Delivering High-Dividend Yields</a>

AGRI

ALLG

AMCX

AVTE

BIMI

BJDX

BMEA

BTDR

CETX

CNSP

EVTV

FCEL

FLFV

KAVL

LRHC

LXRX

MBIO

MEDS

MIRM

MYTE

NDRA

OUST

OVID

PRMW

SCNI

SCPX

SPCE

SYNX

TRNR

VERO

WKHS

XPOF

XTLB

XXII

Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Analyst John Newman from Canaccord Genuity maintained a Buy rating on Atara Biotherapeutics (ATRA – Research Report) and keeping the price target a...

Atara Biotherapeutics: A Promising Buy on Pipeline Progress and Strong Financial Outlook

In a report released on August 16, Benjamin Burnett from Stifel Nicolaus maintained a Hold rating on Atara Biotherapeutics (ATRA – Research Report)...

Atara Biotherapeutics (ATRA) Gets a Hold from Stifel Nicolaus

H.C. Wainwright analyst Robert Burns has reiterated their neutral stance on ATRA stock, giving a Hold rating on August 16. Robert Burns has given h...

Atara Biotherapeutics: Hold Rating Maintained Amid Financial Shortfalls and Regulatory Uncertainties

Comments

Atara Biotherapeutics

Atara Biotherapeutics (ATRA) Opzioni

Atara Biotherapeutics (NASDAQ:ATRA) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO